Longeveron IncChange company Symbol lookupSelect an option...LGVN Longeveron IncPPIH Perma-Pipe International Holdings IncDPDW Deep Down IncWOLF Wolfspeed IncPAVM PAVmed IncCNBP Cornerstone Bancorp IncUPS United Parcel Service IncRHHBY Roche Holding AGEGP Eastgroup Properties IncPMT PennyMac Mortgage Investment TrustGo
Longeveron Inc. is a clinical stage biotechnology company, which is developing cellular therapies for specific aging-related and life-threatening conditions. The Company's lead investigational product is the LOMECEL-B cell-based therapy product (Lomecel-B), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. It is sponsoring phase I and II clinical trials in various indications, such as aging frailty, Alzheimer's disease (AD), metabolic syndrome, acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). It is evaluating Lomecel-B as a therapy for aging frailty and is being designed to reduce inflammation associated with aging frailty and to promote an anti-inflammatory state by releasing anti-inflammatory molecules, which can promote physiological restoration to a more normal state. The Company has completed two multicenter trials in the United States for aging frailty.
|
|
|
|
| |
Upcoming Events
Past Earnings
GAAP vs. Non-GAAP Earnings
TD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts.
| Date | Event description | Earnings per share actual | Earnings estimate range | Previous year's actual |
|---|---|---|---|---|
| May 13, 2022 | Q1 2022 Earnings Release | -$0.17 | -$0.24 to -$0.21 | -- |
| March 11, 2022 | Q4 2021 Earnings Release | -$0.20 | -$0.25 to -$0.25 | -- |
Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.
, , , Copyright © 2022. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.